Terminated PHASE2 INTERVENTIONAL 3-arm NCT02202746

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

Sponsor: Clovis Oncology, Inc.

Conditions Breast Cancer ER Estrogen Receptor Positive HER2 HER2 Positive MBC Metastatic Breast Cancer Triple Negative

Interventions Lucitanib

Updated 13 times since 2017 Last updated: Jun 20, 2020 Started: Sep 9, 2014 Primary completion: Jan 17, 2017 Completion: Jan 18, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to end monotherapy development of the compound in breast cancer.

Other terminated trials from Clovis Oncology, Inc.

More terminations from Clovis Oncology, Inc.

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT02202746, this PHASE2 trial focuses on Breast Cancer and ER and remains terminated or withdrawn. Sponsored by Clovis Oncology, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 8 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2
Jul 2020 — Jan 2021 [monthly]

Terminated PHASE2
Sep 2019 — Jul 2020 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Aug 2019 — Sep 2019 [monthly]

Completed PHASE2
Oct 2018 — Aug 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clovis Oncology, Inc.

Data source: Clovis Oncology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Bakersfield, United States , Baltimore, United States , Boston, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Deerfield Beach, United States , Fort Worth, United States , Fullerton, United States and 18 more locations